DAX24.378 ±0,0%Est505.629 -0,4%MSCI World4.356 +0,4%Top 10 Crypto17,21 +1,2%Nas22.984 +0,9%Bitcoin106.983 +1,4%Euro1,1714 -0,1%Öl65,39 +1,6%Gold3.958 +1,8%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
DroneShield A2DMAA Rheinmetall 703000 Plug Power A1JA81 AMD (Advanced Micro Devices) 863186 NVIDIA 918422 RENK RENK73 Tesla A1CX3T HENSOLDT HAG000 Siemens Energy ENER6Y Novo Nordisk A3EU6F NEL ASA A0B733 D-Wave Quantum A3DSV9 BASF BASF11 Palantir A2QA4J Lufthansa 823212
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
'Shutdown' bleibt bestehen: DAX letztlich kaum bewegt -- US-Börsen uneins -- AMD und OpenAI mit Milliardendeal -- Tesla, Alibaba, BYD, D-Wave, DroneShield, Plug Power, Rheinmetall & Co. im Fokus
Top News
Neues Rekordhoch: Fiskalische Sorgen lassen Bitcoin steigen Neues Rekordhoch: Fiskalische Sorgen lassen Bitcoin steigen
Apex Critical Metals-Aktie gefragt: Starker Kursanstieg nach positiven Nachrichten über Niob-Vorkommen und seltene Erden Apex Critical Metals-Aktie gefragt: Starker Kursanstieg nach positiven Nachrichten über Niob-Vorkommen und seltene Erden
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Sie schätzen die Produkte, Services und stete Erreichbarkeit von BNP Paribas? Dann freuen wir uns, über Ihre Stimme zur Wahl des Zertifikatehauses.

Amgen Aktie

Kaufen
Verkaufen
Amgen Aktien-Sparplan
250,70 EUR -2,80 EUR -1,10 %
XETRA
293,74 USD -4,26 USD -1,43 %
BTT
Amgen jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.137,14 Mrd. EUR

KGV34,48Div. Rendite3,45%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN867900

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS0311621009

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolAMGN

Amgen Aktien News

DatumMeistgelesen
PR NewswireAMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDEND
PR NewswireAMGEN ANNOUNCES $1 BILLION MANUFACTURING EXPANSION IN NORTH CAROLINA
PR NewswireAMGEN TO PRESENT AT CITI'S 2024 GLOBAL HEALTHCARE CONFERENCE
PR NewswireAMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE
PR NewswireAMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY
PR NewswireAMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM
PR NewswireAMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT
PR NewswireAMGEN PRESENTS NEW DATA ACROSS RARE INFLAMMATORY DISEASES AT ACR 2024
PR NewswireAMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA
PR NewswireAMGEN TO PRESENT AT THE 2024 UBS GLOBAL HEALTHCARE CONFERENCE
PR NewswireTEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
PR NewswireAMGEN ANNOUNCES 2024 FOURTH QUARTER DIVIDEND
PR NewswireAMGEN ANNOUNCES WEBCAST OF 2024 THIRD QUARTER FINANCIAL RESULTS
PR NewswireAMGEN PRESENTS POSITIVE PHASE 3 DATA FOR UPLIZNA® (INEBILIZUMAB-CDON) IN GENERALIZED MYASTHENIA GRAVIS (GMG) AT AANEM 2024
PR NewswireLA LA ANTHONY PARTNERS WITH AMGEN TO SHARE CANDID, BEHIND-THE-SCENES LOOK AT HOW PLAQUE PSORIASIS AFFECTS HER LIFE
PR NewswireTEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE
PR NewswireAMGEN TO HOST CONFERENCE CALL TO DISCUSS NEW TOPLINE DATA IN INFLAMMATION AND RARE DISEASE
PR NewswireAMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024
PR NewswireAMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA™ (TARLATAMAB-DLLE) IN SMALL CELL LUNG CANCER AT WCLC 2024
PR NewswireAMGEN TO PRESENT AT THE 2024 WELLS FARGO HEALTHCARE CONFERENCE
PR NewswireAMGEN TO PRESENT AT THE MORGAN STANLEY 22ND ANNUAL GLOBAL HEALTHCARE CONFERENCE
PR NewswireAMGEN ANNOUNCES 2024 THIRD QUARTER DIVIDEND
PR NewswireAMGEN ANNOUNCES WEBCAST OF 2024 SECOND QUARTER FINANCIAL RESULTS
PR NewswireFDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE
PR NewswireAMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024
PR NewswireAMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
PR NewswireAMGEN ANNOUNCES POSITIVE RESULTS FOR PHASE 3 REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN G4-RELATED DISEASE (IgG4-RD)
PR NewswireAMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
PR NewswireAMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024
PR NewswireFDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
PR NewswireAMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024
PR NewswireAMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
PR NewswireAMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
PR NewswireAMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024
PR NewswireAMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS
PR NewswireAMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY
PR NewswireAMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
PR NewswireAMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024
PR NewswireAMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND
PR NewswireAMGEN TO PRESENT AT THE 44TH ANNUAL TD COWEN HEALTH CARE CONFERENCE

Amgen News

Amgen News: auf dieser Seite finden Sie alle Amgen News und Nachrichten zur Amgen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Amgen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Amgen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.